Vaxart Announces Publication Of Preclinical Study Results Evaluating Its Oral Mucosal Vaccine Platform Against Highly Pathogenic Avian Influenza H5N1; Candidate VXA-H5-02 Induced Robust Cross-Neutralizing Antibodies
Publication of positive preclinical study results evaluating its adenovirus-based oral mucosal vaccine platform against Highly Pathogenic Avian Influenza (HPAI) H5N1, a pathogenic virus that poses a significant threat
Vaxart's early lab tests show their pill vaccine works against bird flu. Watch whether this moves toward real human testing and if other companies copy it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.